Bioresponsive Hyaluronic Acid-Based Hydrogel Inhibits Matrix Metalloproteinase-2 in Glioblastoma Microenvironment.

IF 3.6 4区医学 Q2 CHEMISTRY, MEDICINAL

ChemMedChem Pub Date : 2025-06-24 DOI:10.1002/cmdc.202401040

Federica Barbugian, Domenico Salerno, Elisa Ballarini, Luca Crippa, Oscar Francesconi, Francesco Mantegazza, Guido Cavaletti, Stefano Roelens, Gemma Leone, Simone Pepi, Luigi Talarico, Agnese Magnani, Cristina Nativi, Laura Russo

引用次数: 0

Abstract

Glioblastoma multiforme (GBM) is an extremely malignant cancer, resistant to standard therapies. Tumor resection is associated with better outcomes but a complete resection of GBMs is challenging for anatomical limitation and for the high degree of invasiveness. A bioresponsive hydrogel based on hyaluronic acid (HA) cross-linked with a branched metalloproteinase (MMP) inhibitor (MMPI) is proposed. The fully characterized hydrogel, HA-MMPI, presents physical properties suitable for filling the surgical resection cavity and for in situ delivery of the inhibitor. The bioresponsive material selectively inhibits MMP-2 versus MMP-9 in glioblastoma microenvironment.

查看原文本刊更多论文

生物反应性透明质酸基水凝胶抑制基质金属蛋白酶-2在胶质母细胞瘤微环境中的作用。

多形性胶质母细胞瘤（GBM）是一种非常恶性的癌症，对标准治疗有抗药性。肿瘤切除与更好的预后相关，但由于解剖限制和高度侵袭性，完全切除GBMs具有挑战性。提出了一种透明质酸（HA）与支链金属蛋白酶（MMP）抑制剂（MMPI）交联的生物反应性水凝胶。完全表征的水凝胶HA-MMPI具有适合填充手术切除腔和原位递送抑制剂的物理特性。该生物反应材料在胶质母细胞瘤微环境中选择性抑制MMP-2和MMP-9。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

ChemMedChem 医学-药学

CiteScore

6.70

自引率

2.90%

发文量

280

审稿时长

1 months

期刊介绍： Quality research. Outstanding publications. With an impact factor of 3.124 (2019), ChemMedChem is a top journal for research at the interface of chemistry, biology and medicine. It is published on behalf of Chemistry Europe, an association of 16 European chemical societies. ChemMedChem publishes primary as well as critical secondary and tertiary information from authors across and for the world. Its mission is to integrate the wide and flourishing field of medicinal and pharmaceutical sciences, ranging from drug design and discovery to drug development and delivery, from molecular modeling to combinatorial chemistry, from target validation to lead generation and ADMET studies. ChemMedChem typically covers topics on small molecules, therapeutic macromolecules, peptides, peptidomimetics, and aptamers, protein-drug conjugates, nucleic acid therapies, and beginning 2017, nanomedicine, particularly 1) targeted nanodelivery, 2) theranostic nanoparticles, and 3) nanodrugs. Contents ChemMedChem publishes an attractive mixture of: Full Papers and Communications Reviews and Minireviews Patent Reviews Highlights and Concepts Book and Multimedia Reviews.